CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00901147
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:40.234805+00:00
Published At: 2014-06-27T00:00:00+00:00
Record Updated At: 2014-06-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Peripheral T-cell Lymphoma (Not Otherwise Specified)", "Angioimmunoblastic T-cell Lymphoma", "Extranodal NK/T-cell Lymphoma Nasal Type", "Enteropathy- Type T-cell Lymphoma", "Hepatosplenic T-cell Lymphoma", "Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)", "Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2014-06-27"
protocolSection.identificationModule.nctId: "NCT00901147"
protocolSection.identificationModule.officialTitle: "An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.